The AHA urges doctors to begin screening and treating patients who are still in their 30s, well before the risks of a heart attack and stroke are higher.

The American College of Cardiology (ACC), the American Heart Association and nine other leading medical associations, today issued an updated guideline for the management of dyslipidemia-abnormal ...

The prevalence of severely elevated low-density lipoprotein cholesterol (LDL-C) has declined in recent decades, but 1 in 17 US adults in a recent analysis had levels of LDL-C that would warrant ...

An experimental gene therapy for high cholesterol is showing promise in clinical trials and inching closer to approval. The treatment, called VERVE-102, is being tested in people with familial ...

The prevalence of elevated low-density lipoprotein cholesterol (LDL-C) has declined over the past two decades, but 1 in 17 Americans still have a level of 160-189 mg/dL, and 1 in 48 have a level ≥ 190 ...

MANNHEIM, Germany—New international data paint a very dire outlook for patients with homozygous familial hypercholesterolemia (HoFH), with investigators reporting that more than half of deaths that ...

Inclisiran, an siRNA therapy, significantly reduces LDL-C by 28.5% in adolescents with heterozygous familial hypercholesterolemia (HeFH).

Please provide your email address to receive an email when new articles are posted on . CETP inhibition may help high-risk patients reach their LDL goals and reduce risk for atherosclerotic CVD events ...

You get your cholesterol checked at your annual physical, and a few days later, you get back your results. If you’ve ever looked down the list of acronyms and felt at a loss of how to make sense of ...

An experimental treatment called VERVE-102 lowers the amount of "bad" cholesterol in the blood of people with specific cholesterol-raising conditions. When you purchase through links on our site, we ...